- Home
- AMPX vs NYXH Comparison
AMPX vs NYXH Comparison
Compare AMPX & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPX
- NYXH
- Stock Information
- Founded
- AMPX 2008
- NYXH 2009
- Country
- AMPX United States
- NYXH Belgium
- Employees
- AMPX N/A
- NYXH N/A
- Industry
- AMPX Industrial Machinery/Components
- NYXH Medical/Dental Instruments
- Sector
- AMPX Miscellaneous
- NYXH Health Care
- Exchange
- AMPX Nasdaq
- NYXH Nasdaq
- Market Cap
- AMPX 261.0M
- NYXH 261.1M
- IPO Year
- AMPX N/A
- NYXH 2021
- Fundamental
- Price
- AMPX $3.35
- NYXH $10.85
- Analyst Decision
- AMPX Strong Buy
- NYXH Strong Buy
- Analyst Count
- AMPX 7
- NYXH 5
- Target Price
- AMPX $8.43
- NYXH $17.00
- AVG Volume (30 Days)
- AMPX 5.2M
- NYXH 64.9K
- Earning Date
- AMPX 11-07-2024
- NYXH 03-13-2025
- Dividend Yield
- AMPX N/A
- NYXH N/A
- EPS Growth
- AMPX N/A
- NYXH N/A
- EPS
- AMPX N/A
- NYXH N/A
- Revenue
- AMPX $17,480,000.00
- NYXH $5,668,079.00
- Revenue This Year
- AMPX $132.87
- NYXH $22.93
- Revenue Next Year
- AMPX $234.98
- NYXH $411.04
- P/E Ratio
- AMPX N/A
- NYXH N/A
- Revenue Growth
- AMPX 196.22
- NYXH 32.65
- 52 Week Low
- AMPX $0.61
- NYXH $4.27
- 52 Week High
- AMPX $4.70
- NYXH $20.00
- Technical
- Relative Strength Index (RSI)
- AMPX 59.22
- NYXH 77.88
- Support Level
- AMPX $3.17
- NYXH $8.86
- Resistance Level
- AMPX $3.90
- NYXH $10.08
- Average True Range (ATR)
- AMPX 0.64
- NYXH 0.60
- MACD
- AMPX 0.02
- NYXH 0.22
- Stochastic Oscillator
- AMPX 57.46
- NYXH 84.81
About AMPX Amprius Technologies Inc.
Amprius Technologies Inc is engaged in the production of silicon anodes for high energy density lithium-ion batteries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. All of its revenues is geographically earned in the United States.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.